Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach

Laurent Peyrin-Biroulet, Silvio Danese, Fraser Cummings, Raja Atreya, Kay Greveson, Burkhard Pieper, Taegyun Kang

Research output: Contribution to journalReview article


Introduction: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. Areas covered: We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion: Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.

Original languageEnglish
Pages (from-to)731-738
Number of pages8
JournalExpert Review of Gastroenterology and Hepatology
Issue number8
Publication statusPublished - Aug 2019


  • Adalimumab/administration & dosage
  • Anti-Inflammatory Agents/administration & dosage
  • Antibodies, Monoclonal/administration & dosage
  • Biosimilar Pharmaceuticals/administration & dosage
  • Crohn Disease/diagnosis
  • Drug Costs
  • Drug Monitoring/economics
  • Early Diagnosis
  • Humans
  • Inflammatory Bowel Diseases/economics
  • Patient Care Team
  • Patient-Centered Care/economics
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors

Fingerprint Dive into the research topics of 'Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach'. Together they form a unique fingerprint.

  • Cite this